ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MYGN vs QDEL // EV/EBITDA & P/E VALUATION

Myriad Genetics Inc. (NASDAQ) VS. QuidelOrtho Corporation (NASDAQ) • 15-METRIC TALLY: MYGN 4 — QDEL 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYGN VS. QDEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MYGN QDEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 69.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.28% -8.80% +9.08 MYGN /fcf-yield <GO>
Operating Margin -47.00% -33.70% -13.30 QDEL /operating-margins <GO>
Net Profit Margin -44.40% -41.50% -2.90 QDEL /net-margins <GO>
Revenue Growth (YoY) -1.60% -1.90% +0.30 MYGN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 4/9 +2.00 MYGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.7 51.1 +21.58 MYGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $638.0M $943.6M -$305.6M QDEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MYGN REV QDEL REV MYGN GROSS % QDEL GROSS % MYGN FCF QDEL FCF
FY 2025 $824.5M $2.73B 69.9% — $1.8M -$83.0M
FY 2024 $837.6M $2.78B 69.9% — -$8.7M -$112.1M
FY 2023 $753.2M $3.00B — — -$110.9M $280.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYGN // BETA —
QDEL // BETA —